Anti-vista antibodies and fragments, uses thereof, and methods of identifying same

Patent metadata

Field	Value
Publication number	US-11987630-B2
Application number	US-202017104287-A
Country	US
Kind code	B2
Filing date	Nov 25, 2020
Priority date	Feb 12, 2016
Publication date	May 21, 2024
Grant date	May 21, 2024

Abstract

The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Methods of identifying anti-VISTA antibodies capable of eliciting certain biological responses are also included.

First claim

What is claimed:

1. A method of identifying an antibody that binds human- V-domain Ig Suppressor of T cell Activation (VISTA) protein or an antigen binding fragment thereof, from a collection of different anti-human VISTA antibodies, wherein said antibody elicits a biological response, comprising:
a) providing an antibody that binds human VISTA, or an antibody fragment thereof, and
b) determining whether the antibody or antibody fragment thereof induces a biological response in vivo in a cynomolgus monkey wherein the biological response comprises all of the following:
i) activation of monocytes;
ii) activation of T cells; and
iii) a decrease in the number of circulating immune cells.

2. The method of claim 1 , wherein:
(i) the antibody or antigen-binding fragment thereof comprises a Fc region that binds to a human Fc receptor on immune cells;
(ii) the antibody or antigen-binding fragment thereof comprises a Fc region that binds to a human CD 16 receptor;
(iii) the biological response is determined by an in vitro assay in a biological sample obtained from the cynomolgus monkey;
(iv) the biological response is determined by an in vitro assay selected from the group consisting of an immunohistochemical (IHC) staining assay, a cytokine release assay, a chemokine release assay, a cell activation assay, a cell proliferation assay, a cell migration assay, and a flow cytometry assay;
(v) the decrease in the number of circulating immune cells of b) iii, comprises a reduction in circulating monocytes, neutrophils, lymphocytes, eosinophils or basophils, or a combination thereof;
(vi) the detected decrease in the number of circulating immune cells of b) iii, is transient;
(vii) the detected biological response further comprises a decrease in the number of granulocytes in bone marrow and spleen; or any combination of (i)-(vii).

Assignees

• Janssen Pharmaceutica Nv

Inventors

• Snyder Linda A
• Powers Gordon
• Ubani Enrique Zudaire
• Marvel Douglas Matthew

Classifications

• G01N33/5752

  of the lungs · CPC title

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• G01N33/57515

  of the breast · CPC title

• C07K16/2827 Primary

  against B7 molecules, e.g. CD80, CD86 · CPC title

• A61K39/39558

  against tumor tissues, cells, antigens · CPC title